company background image
AMRS

AmyrisNasdaqGS:AMRS Stock Report

Market Cap

US$2.1b

7D

-6.6%

1Y

132.2%

Updated

27 Nov, 2021

Data

Company Financials +
AMRS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

AMRS Stock Overview

Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty markets through its consumer brands and as a supplier of sustainable and natural ingredients in Europe, the United States, Asia, Brazil, and internationally.

Amyris Competitors

Celanese

NYSE:CE

US$17.5b

Neste Oyj

HLSE:NESTE

€32.7b

Altair Engineering

NasdaqGS:ALTR

US$5.8b

Renewable Energy Group

NasdaqGS:REGI

US$2.4b

Price History & Performance

Summary of all time highs, changes and price drops for Amyris
Historical stock prices
Current Share PriceUS$6.78
52 Week HighUS$23.42
52 Week LowUS$2.56
Beta1.44
1 Month Change-54.34%
3 Month Change-57.76%
1 Year Change132.19%
3 Year Change37.25%
5 Year Change-46.17%
Change since IPO-97.26%

Recent News & Updates

Nov 19

Amyris Buying Opportunity Created By Q3 Miss, Mega Convert And Potential Revolutionary COVID Vaccine

Big Revenue miss for Q3 due to supply chain shortages and Amyris guides lower for Q4. Surprise $690 million convert is less dilutive (12%, not 18%) and at a beneficially higher effective conversion price ($15.90, not $10.75/share) due to a capped call hedge. Mega overfunding adds about $590 million cash which can be used to pay off debt, finance new plants, acquire IP and assets and allow Amyris to negotiate deals from strength. Potential revolutionary COVID vaccine in 50/50 Joint Venture with ImmunityBio - Clinical trial data in Q1 2022, with an objective of up to 1 billion doses in 2022. Potentially great buying opportunity especially for those that missed the stock a year ago as delays from supply chain shortages and effects of the surprise convert should be temporary.

Nov 04

Amyris: Assessing Financial Capacity To Sustain Organic Growth, Carry COVID Research And Pay For Acquisition

Amyris, a synthetic clean health and beauty biology company, is a key supplier of sustainable and natural ingredients and possesses some strong consumer brands too. Lack of market enthusiasm following the MG Empower deal points to investors having some doubts about financial capacity in view of the amount of cash in the balance sheet. Also, the company has a collaboration for COVID vaccine development implying expenses for clinical trials. The company has used equity financing for acquisitions of brands before, but, for this one, it will probably require an equity offering exercise. Still, experiencing robust organic growth in consumer and ingredients, with some advantageous COVID collaborations and considering the revenue and cost synergies, the stock is a buy.

Shareholder Returns

AMRSUS ChemicalsUS Market
7D-6.6%-2.6%-2.7%
1Y132.2%19.9%21.3%

Return vs Industry: AMRS exceeded the US Chemicals industry which returned 19.9% over the past year.

Return vs Market: AMRS exceeded the US Market which returned 21.3% over the past year.

Price Volatility

Is AMRS's price volatile compared to industry and market?
AMRS volatility
AMRS Average Weekly Movement13.3%
Chemicals Industry Average Movement5.2%
Market Average Movement6.0%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market2.3%

Stable Share Price: AMRS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: AMRS's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2003595John Melohttps://www.amyris.com

Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty markets through its consumer brands and as a supplier of sustainable and natural ingredients in Europe, the United States, Asia, Brazil, and internationally. It manufactures and sells products for the health and wellness, clean beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks.

Amyris Fundamentals Summary

How do Amyris's earnings and revenue compare to its market cap?
AMRS fundamental statistics
Market CapUS$2.09b
Earnings (TTM)-US$417.13m
Revenue (TTM)US$356.79m

5.9x

P/S Ratio

-5.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AMRS income statement (TTM)
RevenueUS$356.79m
Cost of RevenueUS$208.20m
Gross ProfitUS$148.58m
ExpensesUS$565.72m
Earnings-US$417.13m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.35
Gross Margin41.64%
Net Profit Margin-116.91%
Debt/Equity Ratio-552.7%

How did AMRS perform over the long term?

See historical performance and comparison

Valuation

Is Amyris undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AMRS ($6.78) is trading below our estimate of fair value ($47.36)

Significantly Below Fair Value: AMRS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AMRS is unprofitable, so we can't compare its PE Ratio to the US Chemicals industry average.

PE vs Market: AMRS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AMRS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AMRS has negative assets, so we can't compare its PB Ratio to the US Chemicals industry average.


Future Growth

How is Amyris forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

69.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AMRS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: AMRS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AMRS's is expected to become profitable in the next 3 years.

Revenue vs Market: AMRS's revenue (27.9% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: AMRS's revenue (27.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AMRS's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Amyris performed over the past 5 years?

-27.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AMRS is currently unprofitable.

Growing Profit Margin: AMRS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AMRS is unprofitable, and losses have increased over the past 5 years at a rate of 27.8% per year.

Accelerating Growth: Unable to compare AMRS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AMRS is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (24.1%).


Return on Equity

High ROE: AMRS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is Amyris's financial position?


Financial Position Analysis

Short Term Liabilities: AMRS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: AMRS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: AMRS has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: AMRS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AMRS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AMRS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.4% each year


Dividend

What is Amyris's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AMRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AMRS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AMRS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AMRS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AMRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average management tenure


CEO

John Melo (55 yo)

14.83yrs

Tenure

US$1,344,913

Compensation

Mr. John G. Melo has been the Chief Executive Officer and Director at Amyris, Inc. since January 2007 and has been its President since June 2008. As President and Chief Executive Officer, Mr. Melo has led...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD1.34M) is below average for companies of similar size in the US market ($USD3.64M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: AMRS's management team is considered experienced (4.2 years average tenure).


Board Members

Experienced Board: AMRS's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: AMRS insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.9%.


Top Shareholders

Company Information

Amyris, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Amyris, Inc.
  • Ticker: AMRS
  • Exchange: NasdaqGS
  • Founded: 2003
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: US$2.090b
  • Shares outstanding: 308.24m
  • Website: https://www.amyris.com

Number of Employees


Location

  • Amyris, Inc.
  • 5885 Hollis Street
  • Suite 100
  • EmeryVille
  • California
  • 94608
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/27 23:01
End of Day Share Price2021/11/26 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.